PREVENT Cancer Preclinical Drug Development Program
Ended Master IDIQ Awarded
- Federal agency
-
National Cancer Institute
- Awardees
- 3
- Task orders
- 2
- Obligated
- $4,449,287
Vehicle facts
- Opportunity
-
- N01CN8700618 Solicitation number
- Agency
-
- National Cancer Institute National Institutes of Health, Department of Health and Human Services
- Combined task order value
-
- $4,449,287 Current, with exercised options
- $5,495,522 Potential, with all options
- Last date to order 100% complete
- Shared ceiling 9% used
- $49,995,000.00
IDV award and task order details come from SAM.gov/FPDS.
About this vehicle
The National Cancer Institute (National Institutes of Health, Department of Health and Human Services) established this Master IDIQ on August 14, 2019, for cGMP production of vaccines and biologicals for cancer prevention, with a shared ceiling of $49.995 million and ordering authority that closed on January 24, 2024 — the vehicle is no longer open for new orders.
The PREVENT Cancer Preclinical Drug Development Program is inactive and substantially underutilized. Only two task orders have been awarded across the vehicle's lifetime: the first in September 2019 and the most recent in February 2021, producing an average of roughly 0.33 orders per year. The combined potential value of awarded orders is $5.5 million against a $49.995 million ceiling, representing just 11% of available capacity. Of the $5.5 million potential, $4.4 million has been obligated (81%), with the most recent award closing in May 2024.
Work contracted centers on cGMP manufacturing and R&D services for cancer-preventive vaccines. The February 2021 order to Kindred Biosciences, Inc. ($1.3 million potential) covers cGMP resupply of HPV 16L1/16RG1. The September 2019 order to Advanced Bioscience Laboratories, Inc. ($4.2 million potential) focuses on R&D services and cGMP manufacturing for a vaccine targeting frame-shift mutations in microsatellite-instability tumors. Both orders are priced on a cost-plus-fixed-fee basis and carry no set-aside designations.
Competition on this vehicle is minimal. Only two distinct primes have received awards, splitting the potential value roughly 76–24 in favor of Advanced Bioscience Laboratories, Inc. All orders fund the National Cancer Institute, concentrated entirely within HHS.
With ordering closed for more than two years and only two awards in five years of vehicle life, this IDIQ presents limited near-term BD opportunity. Existing primes on the vehicle already dominate the active scope; new entrants would need to monitor whether the contracting office reopens ordering or establishes a successor vehicle in the cancer immunotherapy or therapeutic vaccine space.
Description
PREVENT Cancer Preclinical Drug Development Program: cGMP Production of Vaccines and Biologicals for Cancer Prevention
IDV awards
Latest task orders
| Task order | Awardee | Awarding agency | Obligated | Last action |
|---|---|---|---|---|
| Award of task order #2 (manufacture of a vaccine targeting frame-shift… | Advanced Bioscience Laboratories, Inc. | NCI | $3,873,113 | |
| Cgmp RE-supply of HPV 16L1/16RG1 | Kindred Biosciences, Inc. | NCI | $576,173 |
Top awardees by obligations
| Rank | Awardee | Obligated | Share |
|---|---|---|---|
| 1 | Advanced Bioscience Laboratories, Inc. | $3,873,113 | 87% |
| 2 | Kindred Biosciences, Inc. | $576,174 | 13% |
Top funding agencies by obligations
| Rank | Funding agency | Obligated | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $4,449,287 | 100% |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2023 | -$279,101 |
| FY2021 | $1,014,721 |
| FY2020 | $2,243,667 |
| FY2019 | $1,469,999 |
Quick answers
What is the PREVENT Cancer Preclinical Drug Development Program contract vehicle?
PREVENT Cancer Preclinical Drug Development Program is an indefinite delivery, indefinite quantity (IDIQ) contract vehicle run by National Cancer Institute (National Institutes of Health), awarded on August 14, 2019.
Which companies hold PREVENT Cancer Preclinical Drug Development Program?
3 companies hold PREVENT Cancer Preclinical Drug Development Program's IDV awards, one each. The latest went to Advanced Bioscience Laboratories, Inc. on August 14, 2019. The awardees whose task orders obligated the most are Advanced Bioscience Laboratories, Inc. and Kindred Biosciences, Inc.
How much has been spent through PREVENT Cancer Preclinical Drug Development Program?
2 task orders have been placed under PREVENT Cancer Preclinical Drug Development Program, obligating $4,449,287.
What is the shared ceiling of PREVENT Cancer Preclinical Drug Development Program?
PREVENT Cancer Preclinical Drug Development Program's shared ceiling is $49,995,000; its task orders have used 9% of it.
Which agencies use PREVENT Cancer Preclinical Drug Development Program the most?
The departments whose task orders under PREVENT Cancer Preclinical Drug Development Program obligated the most are Department of Health and Human Services ($4,449,287).
On GovTribe
See this vehicle's full record
- Every IDV award and task order
- Funding by agency, awardee, NAICS and set-aside
- Teaming partners on this vehicle
- Ask GovTribe AI about this vehicle